Last reviewed · How we verify
Rapid and long acting insulin
At a glance
| Generic name | Rapid and long acting insulin |
|---|---|
| Also known as | Novolog/ Humalog, Lantus/ Levemir |
| Sponsor | Albert Einstein College of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (PHASE2, PHASE3)
- Closed Loop From Onset in Type 1 Diabetes (NA)
- Evaluation of the Efficacy and Safety of DBL-4pen Mobile Application in Patients With Type 2 Diabetes (NA)
- Polycystic Ovary Syndrome (PCOS) and Sleep Apnea (PHASE4)
- Bigfoot Unity Real World Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rapid and long acting insulin CI brief — competitive landscape report
- Rapid and long acting insulin updates RSS · CI watch RSS
- Albert Einstein College of Medicine portfolio CI